The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

por Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S
Publicado 2017

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

por Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Parkinson, Rose, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S
Publicado 2018

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

por Kaseb, Ahmed Omar, Kappadath, S Cheenu, Lee, Sunyoung S, Raghav, Kanwal Pratap, Mohamed, Yehia I, Xiao, Lianchun, Morris, Jeffrey S, Ohaji, Chimela, Avritscher, Rony, Odisio, Bruno C, Kuban, Joshua, Abdelsalam, Mohamed E, Chasen, Beth, Elsayes, Khaled M, Elbanan, Mohamed, Wolff, Robert A, Yao, James C, Mahvash, Armeen
Publicado 2021

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harbo...

por Subbiah, Vivek, McMahon, Caitlin, Patel, Shreyaskumar, Zinner, Ralph, Silva, Elvio G, Elvin, Julia A., Subbiah, Ishwaria M., Ohaji, Chimela, Ganeshan, Dhakshina Moorthy, Anand, Deepa, Levenback, Charles F., Berry, Jenny, Brennan, Tim, Chmielecki, Juliann, Chalmers, Zachary R., Mayfield, John, Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S., Ali, Siraj M.
Publicado 2015